| Novelion Therapeutics is a biopharmaceutical company. Through its subsidiary, Co. develops and commercializes two rare disease products, metreleptin and lomitapide. Metreleptin, a recombinant analog of human leptin, is marketed in the U.S. under the brand name MYALEPT (metreleptin) for injection, as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy. Lomitapide is marketed in the U.S. under the brand name JUXTAPID (lomitapide) capsules, as an adjunct to a low-fat diet and other lipid-lowering treatments, including low-density lipoprotein apheresis where available. We show 13 historical shares outstanding datapoints in our coverage of NVLN's shares outstanding history.
Understanding the changing numbers of NVLN shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like NVLN versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching NVLN by allowing them to research NVLN shares outstanding history
as well as any other stock in our coverage universe.